Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended June 30, 2026
Filing Date: September 8, 2026
Context: The registrant filed this report to incorporate by reference its unaudited interim condensed consolidated financial statements, an operating and financial review, and a press release detailing financial results and drug development program updates.
Key Financial Metrics
The provided text serves as a cover sheet and exhibit index for the Form 6-K filing. It references the existence of financial data in Exhibits 99.1, 99.2, and 99.3 but does not contain the specific numerical values for the following metrics:
- Revenue: Not provided in the text.
- Profit/Loss: Not provided in the text.
- Cash Flow: Not provided in the text.
- Margins: Not provided in the text.
- Debt and Liquidity: Not provided in the text.
Note: Specific financial figures are located in the referenced exhibits (99.1, 99.2, 99.3) which are not included in the input content.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. It only confirms that updates on drug development programs and financial results for the six months ended June 30, 2026, were announced.
Guidance, Outlook, and Risks
Outlook and Updates: The press release (Exhibit 99.3) and Operating Review (Exhibit 99.1) contain updates on the Company's drug development programs and forward-looking statements, though the specific content of these updates is not detailed in the cover text.
Risks and Contingencies: No specific risks or contingencies are enumerated in the provided text. The filing incorporates standard forward-looking statement disclaimers by reference to the press release.
Investor Verification Checklist
- Verify the specific revenue and net loss figures in Exhibit 99.2 (Unaudited Interim Condensed Consolidated Financial Statements).
- Review the cash burn rate and remaining cash runway in the Operating and Financial Review (Exhibit 99.1).
- Confirm the status and timeline of drug development programs mentioned in the September 8, 2026 press release (Exhibit 99.3).
- Check for any new material agreements or financing activities disclosed in the full text of the exhibits.